-
Founded in:
1999-02-03 -
Country:
China -
Address:
No. 8 Guangyuan East Street, Tongzhou Industrial Development Zone, Tongzhou District, Beijing -
Tax NO.:
91110112700216160K -
Registered Funds:
480 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Trimetazidine dihydrochloride |
Extract from the above information
More
Extract from the above information |
13171-25-0 | 32 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Repaglinide |
Repaglinide is a short-acting insulin secretagogue that lowers blood sugar levels by promoting the release of insulin from the pancreas. This effect depends on the functional β cells in the pancreatic islets. Repaglinide binds to receptors on β cells to close the ATP-dependent potassium channels in the β cell membrane, depolarizes β cells, opens calcium channels, increases calcium influx, and induces β cells to secrete insulin. After oral administration of repaglinide, patients with type 2 diabetes experience an insulin secretion response within 30 minutes after a meal, causing a decrease in blood sugar during meals.
More
Repaglinide is a short-acting insulin secretagogue that lowers blood sugar levels by promoting the release of insulin from the pancreas. This effect depends on the functional β cells in the pancreatic islets. Repaglinide binds to receptors on β cells to close the ATP-dependent potassium channels in the β cell membrane, depolarizes β cells, opens calcium channels, increases calcium influx, and induces β cells to secrete insulin. After oral administration of repaglinide, patients with type 2 diabetes experience an insulin secretion response within 30 minutes after a meal, causing a decrease in blood sugar during meals. |
135062-02-1 | 43 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Repaglinide |
Repaglinide is a short-acting insulin secretagogue that lowers blood sugar levels by promoting the release of insulin from the pancreas. This effect depends on the functional beta cells in the pancreatic islets. Repaglinide binds to receptors on beta cells to close ATP-dependent potassium channels in the beta cell membrane, depolarizes beta cells, opens calcium channels, increases calcium influx, and induces beta cells to secrete insulin. When patients with type 2 diabetes take repaglinide orally, they experience an insulin secretion response within 30 minutes after a meal, causing blood sugar to drop during meals. Plasma repaglinide levels drop rapidly, and 4 hours after taking the drug, the drug concentration in the plasma of patients with type 2 diabetes is very low. Studies have shown that taking 0.5-4 mg of repaglinide for type 2 diabetes reduces blood sugar concentration in a dose-dependent manner. Clinical research results show that repaglinide should be taken before meals, usually within 15 minutes before meals, and the medication time can also be controlled 0-30 minutes before meals.
More
Repaglinide is a short-acting insulin secretagogue that lowers blood sugar levels by promoting the release of insulin from the pancreas. This effect depends on the functional beta cells in the pancreatic islets. Repaglinide binds to receptors on beta cells to close ATP-dependent potassium channels in the beta cell membrane, depolarizes beta cells, opens calcium channels, increases calcium influx, and induces beta cells to secrete insulin. When patients with type 2 diabetes take repaglinide orally, they experience an insulin secretion response within 30 minutes after a meal, causing blood sugar to drop during meals. Plasma repaglinide levels drop rapidly, and 4 hours after taking the drug, the drug concentration in the plasma of patients with type 2 diabetes is very low. Studies have shown that taking 0.5-4 mg of repaglinide for type 2 diabetes reduces blood sugar concentration in a dose-dependent manner. Clinical research results show that repaglinide should be taken before meals, usually within 15 minutes before meals, and the medication time can also be controlled 0-30 minutes before meals. |
135062-02-1 | 43 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Calcium bis(2-hydroxy-4-(methylthio)butyrate) |
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy
More
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy |
59mg | 4857-44-7 | 9 |
| L-Threonine |
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy
More
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy |
53mg | 72-19-5 | 13 |
| Calcium 3-methyl-2-oxovalerate |
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy
More
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy |
67mg | 66872-75-1 | 10 |
| Ketoleucine calcium salt dihydrate |
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy
More
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy |
101mg | 51828-95-6 | 10 |
| Calcium phenylpyruvate |
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy
More
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy |
68mg | 51828-93-4 | 10 |
| Calcium alpha-ketovaline |
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy
More
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy |
86mg | 51828-94-5 | 10 |
| Lysine acetate |
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy
More
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy |
105mg | 0 | |
| N-[(tert-Butoxy)carbonyl]-D-tryptophan |
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy
More
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy |
twenty threemg | 0 | |
| L-Histidine |
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy
More
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy |
38mg | 71-00-1 | 20 |
| Boc-D-Tyr-OH |
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy
More
Provide essential amino acids and minimize the intake of amino nitrogen; reduce urea synthesis and the accumulation of uremic toxic products; improve renal hyperphosphatemia and secondary hyperparathyroidism; improve renal osteodystrophy |
30mg | 70642-86-3 | 9 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Calcium phenylpyruvate |
Extract from the above information
More
Extract from the above information |
51828-93-4 | 10 |